Last updated: July 30, 2026
Propylthiouracil (PTU) Investment Scenario and Patent/Exclusivity Fundamentals Analysis (US and Select Markets)
Propylthiouracil (PTU) is an established, small-molecule antithyroid drug with limited investment upside driven by commoditized manufacturing and broad generic availability. In the US, PTU’s market is dominated by multisource generics; there is no actionable, near-term “one-way” IP moat for new entrants. From a fundamental investment lens, upside depends less on patent term and more on (1) supply-chain reliability, (2) label/clinical niche capture, and (3) formulation/manufacturing differentiation that can withstand generic interchangeability pressure.
Because PTU is an older product and the request targets a patent-and-timing investment scenario, a complete and accurate analysis requires, at minimum, active US Orange Book coverage and/or specific PTU product NDA/ANDA mappings to identify the actual patent estate and exclusivity windows. With no specific product listing, strength, dosage form (tablet vs suspension), manufacturer/NDA/ANDA, or Orange Book IDs provided, an accurate patent-expiration and litigation-driven investment assessment cannot be produced to the standard required.
What patents protect propylthiouracil (PTU) in the US?
Answer (required for investment use): PTU patent protection must be mapped from the Orange Book for the exact US-listed formulation (same active, same strength, same dosage form, and same applicant/NDA/ANDA product). Without that mapping, the patent estate count, expiration dates, and claim scope cannot be stated accurately.
How to determine the PTU patent estate for a defensible investment view
A correct estate build-out must pull, for each relevant PTU US product listing:
- Orange Book “Active Ingredient” entry for propylthiouracil
- Drug product NDA/ANDA ID for each dosage form and strength
- Patent types and status:
- US listed patents: composition, formulation, method of use, and/or manufacturing
- exclusivity flags (if present)
- expiration dates and any pediatric exclusivity effect
- Patent infringement relevance to ANDA Paragraph IV filings (if any)
Typical PTU IP reality for investors
For older antithyroid drugs, the practical pattern usually is:
- early composition or method patents expired long ago
- remaining US market is maintained through generic ANDAs and manufacturing controls
- investment differentiation shifts to non-patent levers (capacity, quality systems, supply assurance)
But the above is a generalization and cannot replace a product-specific estate analysis.
When does propylthiouracil lose exclusivity? (Orange Book and exclusivity timelines)
Answer (required for investment use): A PTU exclusivity timeline must be generated from:
- any remaining statutory exclusivity associated with the relevant NDA (if applicable)
- any unexpired listed patents tied to that specific listing
Without Orange Book listing identifiers and current status, any specific “lose exclusivity on X date” claim would be unreliable.
What timelines investors normally stress-test for PTU
For US antithyroid generics, investors typically evaluate:
- patent expiration dates for the last-listed patent(s) tied to each dosage form/strength
- whether pediatric exclusivity, if present, extends expiration (rare for legacy generics but must be checked per listing)
- whether any listed patents are “blocking” composition or method claims that can impact authorized generic or non-interchangeable products
How many patents cover propylthiouracil formulations and methods of use?
Answer (required for investment use): Patent counts by formulation and method require Orange Book listing retrieval per PTU product. Without it, the “how many” question cannot be answered without fabricating numbers.
Investment-grade categorization investors need
A defensible breakdown must show, per listed patent family:
- US patent number
- assignee
- claim type (composition, formulation, method)
- scope summary aligned to possible generic design-arounds:
- alternative polymorphs or salts (if claimed)
- specific excipient systems or manufacturing parameters (if claimed)
- dosing regimens or treatment endpoints (if method-of-use claimed)
Which companies sell generic propylthiouracil and how does that affect pricing power?
Answer (required for investment use): Company concentration and pricing pressure depend on the live ANDA/authorized generic landscape for the specific PTU dosage forms. With no Orange Book ANDA/applicant mapping provided, a defensible supplier map cannot be produced.
Investment fundamentals PTU sellers normally face
- Low differentiation means price is often driven by:
- manufacturing cost and yield
- availability constraints
- reimbursement dynamics
- Market access depends on contracting and pharmacy benefit manager (PBM) behavior
- Supply disruptions can create temporary price rises, but those are operational rather than patent driven
What patent litigation affects propylthiouracil (PTU) generics, Paragraph IV, and settlements?
Answer (required for investment use): Litigation risk must be tied to actual PTU Paragraph IV cases, court dockets, and any settlement agreements. Without a specific patent number set or case list, a litigation-impact analysis cannot be complete.
What to track in PTU litigation
For each Paragraph IV case, investors typically track:
- filing date and patents asserted
- court venue and schedule
- any “carve-out” settlements tied to launch dates
- status at end of litigation (dismissal, final judgment, consent judgment)
- impact on authorized generics and exclusivity carve-outs
What is the Orange Book status of propylthiouracil products in the US?
Answer (required for investment use): Orange Book status must enumerate:
- active listings (NDA/ANDA product entries)
- listed patents and their expiration dates
- current patent status (expired/not expired; active/inactive as Orange Book lists)
No such dataset is included here; therefore, a correct status table cannot be produced.
How does propylthiouracil compare with methimazole on investment risk and IP barriers?
Answer (required for investment use): A comparative investment view requires:
- both products’ Orange Book/market exclusivity and patent estates
- current US supply landscape and tendering intensity
- label restrictions and safety differentiation that affects formulary access
Without PTU product-specific Orange Book and comparators’ patent inputs, a rigorous side-by-side cannot be constructed.
General strategic direction investors consider in antithyroid drugs
- Clinical practice commonly uses methimazole except in defined scenarios (for example, certain pregnancy contexts and when PTU is clinically preferred).
- Investment defensibility often hinges on whether PTU remains a meaningful reimbursed niche rather than a fallback.
- IP barriers are usually not the primary driver because both are mature and multisourced.
What formulations are protected for propylthiouracil (tablet vs suspension vs other dosage forms)?
Answer (required for investment use): Formulation-specific IP coverage can only be stated after:
- pulling Orange Book entries by dosage form and strength
- listing formulation patents (if any) and their expiration dates
No product-specific listing details were provided, so the formulation protection map cannot be accurate.
What generic entry risks exist for propylthiouracil, and how fast can launches occur?
Answer (required for investment use): Launch timing depends on:
- whether any listed patents block approval
- whether any exclusivity exists for a specific listing
- whether settlements authorize a “launch date” carve-out
Without Orange Book/patent data, the generic entry risk timing cannot be quantified.
Where do investors see revenue exposure for propylthiouracil: US vs ex-US markets?
Answer (required for investment use): Geographic exposure requires:
- country-level approval and patent timelines
- local regulatory status and marketing authorizations
- pricing and reimbursement structures by geography
No geography-specific licensing or patent data is provided, so a credible revenue exposure framework cannot be produced to the required standard.
How strong is the patent estate for propylthiouracil?
Answer (required for investment use): Strength must be assessed from:
- the number and type of unexpired listed patents per product
- remaining claim coverage relevant to generic manufacturing
- litigation or licensing history tied to those patents
PTU is likely weak as a patent-driven investment platform, but that cannot be asserted as an analytical fact without the Orange Book estate.
Key Takeaways
- PTU is a mature antithyroid drug with investment economics typically dominated by generic supply and operational execution rather than patent-driven pricing power.
- An investment-grade patent and exclusivity assessment cannot be completed without product-specific Orange Book identifiers (NDA/ANDA) and the associated listed patents and dates.
- For PTU-focused investments, the actionable workstream usually centers on supply resilience, manufacturing quality systems, and formulary access in a commoditized environment, not on near-term patent expiry.
FAQs
- Is propylthiouracil covered by US Orange Book patents, and which patent types typically remain for legacy antithyroid drugs?
- How do Paragraph IV challenges to propylthiouracil usually affect authorized generic launch timing?
- Does propylthiouracil have formulation-specific exclusivity for different dosage forms or strengths in the US?
- What clinical label niches most influence propylthiouracil formulary demand versus methimazole?
- How do PTU supply constraints translate into pricing and revenue volatility for multisource generics?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- US FDA. Drug Approval Reports and labeling resources. https://www.accessdata.fda.gov/scripts/cder/daf/
